about
Galectin-3 regulates myofibroblast activation and hepatic fibrosisLiver transplantation for viral hepatitis in 2015Markers of acute rejection and graft acceptance in liver transplantationRole of antiviral therapy in the natural history of hepatitis B virus-related chronic liver diseaseWho fares worse after liver transplantation? Impact of donor and recipient variables on outcome: data from a prospective study.Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudySystemic administration of a novel human umbilical cord mesenchymal stem cells population accelerates the resolution of acute liver injury.Therapeutic application of stem cells in gastroenterology: an up-date.Hepatic stem cells: from inside and outside the liver?Experimental hepatology applied to stem cells.Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma.Fibrosis progression and the pros and cons of antiviral therapy for hepatitis C virus recurrence after liver transplantation: a review.Stem and progenitor cells in liver regeneration and repair.Adherence in liver transplant recipients.Hepatitis C virus infection in end-stage renal disease and kidney transplantation.Hepatitis C virus and liver transplantation: where do we stand?Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents.Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation.Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.Recent advances in understanding and managing liver transplantationThe Seville expert workshop for progress in posttransplant lymphoproliferative disorders.Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.Use of grafts from anti-HBc-positive donors in liver transplantation: a 5-year, single-center experience.Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors.Umbilical cord mesenchymal stem cells modulate dextran sulfate sodium induced acute colitis in immunodeficient miceRisk factors in liver retransplantation: a single-center experience.Heparanase and macrophage interplay in the onset of liver fibrosis.Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.Prognostic evaluation of the donor risk index among a prospective cohort of Italian patients undergoing liver transplantation.The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice.Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury.Risk factors for central pontine and extrapontine myelinolysis after liver transplantation: a single-center study.A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis.Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins.Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation.Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation.
P50
Q24546358-6E6F158E-00A7-440B-8CEC-50583A6A8716Q26773224-2355D615-C738-4A24-8235-A564CC7FBBD3Q28088272-928A7D93-49C9-4684-AED9-7ECB6AE550FDQ28088566-59ACBB6C-5646-4EA7-AE62-FCEF5FFBE783Q30636652-6E0E1328-EC4A-4866-A18B-BA0002360646Q31168033-E23F7FA3-62FB-4EB9-8EF4-6EA1D9F81EC6Q34334408-3D4BFF05-F650-48A1-B7C6-27375381AFD3Q35404189-02FB7427-8F4E-4FA9-B87D-BBF8FC59949EQ35660987-279A5364-584B-45E0-8D26-DDC0E0CA8F03Q36998753-98DA6CBD-ABB1-48C1-8C82-6EDCE25171D1Q37028389-30A49C3B-5343-463E-B504-A8AAC16DDAFBQ37778561-5ABCDA1B-0C58-48C4-A8A5-ED3D673EDC69Q37828509-12431301-F976-495D-977A-534BF7994D25Q37850768-5C14291D-DD5E-49F4-88A9-7E88F5093F7BQ38213956-04354849-4C4D-4B2B-8427-F83E46475B81Q38551818-490B76C3-3C52-43CE-88FC-D1996A326BA6Q38712605-18DB7AB6-48B3-41C4-BB53-C96CB4ED4BCAQ38763789-64119316-7ECA-4E13-A36D-9F01AA020BADQ38859081-A1615DE9-9656-477C-A623-32116C857E16Q38980269-9A87373E-F423-4155-BB43-7AFF178AEC06Q38986603-432D92D2-DAB0-4843-8F4F-924B3B302809Q39095917-36243BDA-B5EF-46F8-99A4-BD5A0EC53D8BQ39550390-0BA329F0-050E-485E-8038-BBF14A6CBB2EQ40121053-013DAA7A-FB40-422F-BF30-F8329192D8ACQ41085476-2E86FED2-ED6F-4722-9BF4-8DA3CC1BB3F9Q41924669-A7C3433C-8E8C-4926-898D-FEB9903DFFE1Q42269890-AF46A2BB-E48A-474A-88F9-680B29532B07Q42369605-695EEB82-DEA9-4A91-BE72-1718918AED43Q42720537-F20A166D-2316-42E2-AB40-B06BD7C11A23Q43686619-FA694E0E-F8F9-4F01-83CE-7790B95301EFQ43812376-FD857A5A-D8EB-47F4-999E-EBC390050D65Q45384068-E1E6596D-2695-4773-822F-BBE061FF449AQ45934958-7F3D56DA-037A-4E6E-BBED-71371AB1C0B1Q46914175-BED5B6D8-A893-4A13-9937-4DA6431DB6A4Q47566425-EFA1E7BE-7AC4-43B2-8DC9-6B80FDF0C67AQ47786226-07EFFF58-392B-4836-94A1-DB07125281C7Q47839389-BA828285-F51F-4469-BE1D-2ABE0DEBFB54Q48613680-095AD461-6E7E-455E-9B6E-A161B4815A1DQ51715162-DF5BA366-DDFB-44E6-97A1-3923A0184A54Q51767959-18B989F0-1D96-461E-BAFB-CAD3A3EAD3C9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesco P Russo
@ast
Francesco P Russo
@en
Francesco P Russo
@es
Francesco P Russo
@nl
type
label
Francesco P Russo
@ast
Francesco P Russo
@en
Francesco P Russo
@es
Francesco P Russo
@nl
prefLabel
Francesco P Russo
@ast
Francesco P Russo
@en
Francesco P Russo
@es
Francesco P Russo
@nl
P106
P1153
36341243900
P21
P31
P496
0000-0003-4127-8941